Stada, a sizable German pharmaceutical company, announced plans to move part of its production capabilities from Western and Central Europe to its Russian-based assets, the Russian regional daily Delovoy Kvartal reported following an interview with Dr. Stephan Eder, executive vice president of Stada Russia/CIS.

The Germans want to localize in Russia the manufacture of products that are currently made in England and in Serbia. Pharmaceuticals made in Russia will be marketed both domestically and internationally.

Nizhny Novgorod in the mid-Volga region (Nizhpharm, the factory owned by Stada since 2005) and Obninsk outside Moscow will be the key localization sites. In both cities, Stada already has a 70% level of localization, one of Russia’s deepest.

In addition to that, Stada is considering pushing Russian-based projects in health care digitization.

According to Dr. Eder, Russia is Stada’s second most important market. The source quoted him as saying that in addition to an estimated ˆ1bn already invested in Russia, the German company has three-year plans to invest in Russian-based manufacture another ˆ13m.